Format

Send to

Choose Destination
Int J Oncol. 2011 Jul;39(1):235-43. doi: 10.3892/ijo.2011.1028. Epub 2011 May 3.

Phosphorylation of β-catenin results in lack of β-catenin signaling in melanoma.

Author information

1
University of Regensburg, Institute of Pathology, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany. skuphal@gmx.de

Abstract

The Wnt/β-catenin pathway is involved in differentiation events during embryonic development and is further described as a pathway often participating in tumor formation when aberrantly activated. Molecular studies concentrating on colorectal cancer revealed mutations of apc, ctnnbi, btrc and tcf-4 genes which mimic Wnt stimulation. However, such mutations are rarely found during melanoma development. Therefore, we analyzed the β-catenin activity in this type of skin cancer. Interestingly, localization of β-catenin protein was basically cytoplasmic in melanomas in vivo, which was in clear contrast to findings in colon carcinoma. Congruently, the transcriptional activity of β-catenin regulating expression of β-catenin target genes was not observed in several melanoma cell lines. Further, neither LiCl nor Wnt agonist treatment led to significant activation of β-catenin signaling. This lack in functionality seems to depend on phosphorylation at threonine 41 and serine 45 of β-catenin observed in several melanoma cell lines. However, this specific endogenous phosphorylation pattern led to upregulation of other signaling pathways resulting e.g. in induction of N-cadherin expression. In summary, this study suggests a cell type-specific regulation of β-catenin function. This alternative β-catenin signaling pathway should be considered when thinking about targeting β-catenin in melanoma treatment.

PMID:
21584489
DOI:
10.3892/ijo.2011.1028
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Spandidos Publications
Loading ...
Support Center